Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069925 | 0.90 | PIK3R1 (0.38) | PIK3R1PIK3CAMTORPDE4BPDE7A | |
| SCHEMBL369542 | 0.90 | MRGPRX4 (0.38) | GPR119PDE4BPDE7ATLR9TLR7 | |
| SCHEMBL15097386 | 0.89 | LRRK2 (0.42) | LRRK2PIK3CAMTOR | |
| SCHEMBL368957 | 0.89 | TP53 (0.38) | LRRK2PIK3R1PIK3CAGPR119MTOR | |
| SCHEMBL369852 | 0.87 | TLR9 (0.41) | GPR119PDE4BPDE7AYAP1TLR9 | |
| SCHEMBL367324 | 0.86 | PDE4B (0.38) | GPR119PDE4BPDE7AYAP1PRMT5 | |
| SCHEMBL368809 | 0.86 | PDE4B (0.38) | GPR119PDE4BPDE7AYAP1PRMT5 | |
| SCHEMBL15092068 | 0.85 | TLR9 (0.43) | GPR119PDE4BPDE7ATLR9TLR7 | |
| SCHEMBL368745 | 0.84 | TLR9 (0.37) | PDE4BPDE7AYAP1PRMT5TLR9 | |
| SCHEMBL368710 | 0.83 | TLR9 (0.40) | GPR119PDE4BPDE7AYAP1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| EP-2593460-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | Avexa Limited (AU) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | LRRK2 2544/4885PIK3R1 2320/4885PIK3CA 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.